Last reviewed · How we verify

Verity Pharmaceuticals Inc. — Portfolio Competitive Intelligence Brief

Verity Pharmaceuticals Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Bacillus Calmette-Guerin: Strain TICE Bacillus Calmette-Guerin: Strain TICE phase 3 Live attenuated vaccine / Immunotherapy Pattern recognition receptors (TLR2, TLR4, NOD2); non-specific immune activation Oncology / Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Alliance for Clinical Trials in Oncology · 1 shared drug class
  2. Massachusetts General Hospital · 1 shared drug class
  3. Memorial Sloan Kettering Cancer Center · 1 shared drug class
  4. Nottingham University Hospitals NHS Trust · 1 shared drug class
  5. Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 1 shared drug class
  6. TASK Applied Science · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Verity Pharmaceuticals Inc.:

Cite this brief

Drug Landscape (2026). Verity Pharmaceuticals Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/verity-pharmaceuticals-inc. Accessed 2026-05-16.

Related